Company History
(History04 2014-)

Launched Pulmonary Arterial Hypertension agent Uptravi® in the US. Since then, launched in Europe and other countries.

Completed construction of Active Pharmaceutical Ingredient Manufacturing Building in the headquarter areas

Received the Minister of State for Special Missions Award for "Nippon Shinyaku children's literary awards "children's literary awards

Completed construction of manufacturing facility for highly active solid formulations in Odawara Central Factory

Introduced industry-first "MR flextime system" as part of work style reform

Presented the results of clinical trials for viltolarsen, a treatment for Duchenne muscular dystrophy (DMD), conducted in Japan and the U.S. at academic conferences held in New Orleans, the U.S., and Mendoza, Argentina

Launched CD20-positive follicular lymphoma agent GAZYVA^®

Started a phased process of applying for approval for the marketing of viltolarsen, a DMD treatment, in the U.S.

Launched sinusoidal obstruction syndrome (hepatic veno-occlusive disease) agent Defitelio^®

Nippon Shinyaku Co., Ltd. celebrated the centenary of its establishment on October 1

Signed the United Nations Global Compact (UNGC) and joined the Global Compact Network Japan(GCNJ)

Launched Duchenne Muscular Dystrophy agent VILTEPSO^® in Japan

Launched Duchenne Muscular Dystrophy agent VILTEPSO^™ injection in U.S.

Established a local subsidiary “Beijing Nippon Shinyaku Co., Ltd.” in Beijing, China

Established a local subsidiary “Tianjin Nippon Shinyaku Co., Ltd.” in Tianjin, China

Selected as a Constituent of the FTSE Blossom Japan Sector Relative Index

Launched Seizures Associated with Dravet syndrome agent Fintepla^®

Launched iron deficiency anemia agent MonoVer^®

Launched High-risk acute myeloid leukemia agent Vyxeos^®

Launched Jaypirca for patients with relapsed or refractory mantle cell lymphoma who are resistant or intolerant to other BTK inhibitors.